6 news items
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
BPTS
12 Jun 24
. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
BPTS
10 Jun 24
be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties
Combined General Meeting of June 24, 2024
BPTS
7 Jun 24
. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
BPTS
14 May 24
be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties
Biophytis is Deploying its Partnership Strategy in Obesity
BPTS
29 Apr 24
be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties
xoixddae92t6rlamgswm9lg7wu5yy6y0n1oiy7w
BPTS
18 Apr 24
are based on assumptions that Biophytis considers to be reasonable.However, there can be no assurance that the statements contained in such forward
- Prev
- 1
- Next